Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 20/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 11/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29823451 | 1.00 | CXCR4 (0.76) | CXCR4CYP3A4CYP2D6 | |
| Bromide SCHEMBL4542845 | 0.99 | CXCR4 (0.75) | CXCR4CYP3A4CYP2D6 | |
| SCHEMBL5788692 | 0.93 | CXCR4 (0.68) | CXCR4CYP3A4CYP2D6 | |
| SCHEMBL29823186 | 0.92 | CXCR4 (0.68) | CXCR4CYP3A4CYP2D6 | |
| SCHEMBL1878540 | 0.92 | CXCR4 (0.68) | CXCR4CYP3A4CYP2D6 | |
| Bromide SCHEMBL4543988 | 0.92 | CXCR4 (0.67) | CXCR4CYP3A4CYP2D6 | |
| SCHEMBL1875171 | 0.90 | CXCR4 (0.76) | CXCR4CYP3A4CYP2D6 | |
| SCHEMBL29823490 | 0.90 | CXCR4 (0.76) | CXCR4CYP3A4CYP2D6 | |
| SCHEMBL29823322 | 0.90 | CXCR4 (0.76) | CXCR4CYP3A4CYP2D6 | |
| SCHEMBL1877199 | 0.90 | CXCR4 (0.76) | CXCR4CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2371361-A1 | Methods to mobilize progenitor/stem cells | Genzyme Global S.à.r.l. (LU) | 2011-10-05 | — | — | EP | claimed |
| US-7935692-B2 | Methods to mobilize progenitor/stem cells | GENZYME CORPORATION (US) | 2011-05-03 | — | — | US | claimed |
| US-20100105915-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2010-04-29 | — | — | US | claimed |
| US-20100035941-A1 | METHODS FOR INCREASING BLOOD FLOW AND/OR PROMOTING TISSUE REGENERATION | GENZYME CORPORATION | 2010-02-11 | — | — | US | claimed |
| EP-1317445-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC (CA) | 2009-03-11 | — | — | EP | claimed |
| US-7183273-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED, INC. (CA) | 2007-02-27 | — | — | US | claimed |
| US-20060264434-A1 | Chemokine receptor binding heterocyclic compounds | ANORMED INC. (CA) | 2006-11-23 | — | — | US | claimed |
| US-20060128750-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2006-06-15 | — | — | US | claimed |
| EP-1163238-B1 | CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC (CA) | 2006-05-31 | — | — | EP | claimed |
| US-20040235823-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2004-11-25 | — | — | US | claimed |
| US-20030018046-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2003-01-23 | — | — | US | claimed |
| US-20250295698-A1 | DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM CELLS | ENSOMA INC (US) | 2025-09-25 | — | — | US | disclosed |
| US-20250032549-A1 | DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS | ENSOMA INC (US) | 2025-01-30 | — | — | US | disclosed |
| US-20240285831-A1 | METHODS OF USE OF MODULATORS TO IMPROVE NERVE REGENERATION | KEEFER, Edward (US) | 2024-08-29 | — | — | US | disclosed |
| US-20240189387-A1 | DOSING REGIMENS FOR HEMATOPOIETIC STEM CELL MOBILIZATION FOR STEM CELL TRANSPLANTS IN MULTIPLE MYELOMA PATIENTS | ENSOMA, INC. | 2024-06-13 | — | — | US | disclosed |
| EP-1317445-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2003-06-11 | — | — | EP | disclosed |
| US-20030018046-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2003-01-23 | — | — | US | disclosed |
| WO-2002022600-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2002-03-21 | — | — | WO | disclosed |
| EP-1163238-A1 | CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000056729-A1 | CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264434-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR4, CXCR1 | CXCR4 2/4885CYP3A4 1330/4885CYP2D6 934/4885 |
| US-20240189387-A1 | DOSING REGIMENS FOR HEMATOPOIETIC STEM CELL MOBILIZATION FOR STEM CELL TRANSPLANTS IN MULTIPLE MYELOMA PATIENTS | CXCL12, MCL1, MYADM | CXCR4 11/4885CYP3A4 4780/4885CYP2D6 4158/4885 |
| US-20100105915-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | CXCR4, CCR5, CXCR3 | CXCR4 1/4885CYP3A4 2524/4885CYP2D6 3280/4885 |
| US-20060128750-A1 | Chemokine receptor binding heterocyclic compounds | CXCR4, CCR5, CXCR3 | CXCR4 1/4885CYP3A4 2593/4885CYP2D6 3062/4885 |
| US-20100035941-A1 | METHODS FOR INCREASING BLOOD FLOW AND/OR PROMOTING TISSUE REGENERATION | CCR2, CXCR4, CXCR2 | CXCR4 2/4885CYP3A4 4455/4885CYP2D6 3954/4885 |
| US-20250032549-A1 | DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS | CXCL12, CD44, CD47 | CXCR4 7/4885CYP3A4 4587/4885CYP2D6 2847/4885 |
| US-20030018046-A1 | Chemokine receptor binding heterocyclic compounds | CXCR3, ACKR3, CCR2 | CXCR4 7/4885CYP3A4 3162/4885CYP2D6 3122/4885 |
| US-20240285831-A1 | METHODS OF USE OF MODULATORS TO IMPROVE NERVE REGENERATION | CXCR3, CXCL12, CXCR4 | CXCR4 3/4885CYP3A4 4854/4885CYP2D6 4798/4885 |
| US-20250295698-A1 | DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM CELLS | CXCL12, CSF3R, THPO | CXCR4 12/4885CYP3A4 4834/4885CYP2D6 4134/4885 |
| US-20040235823-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR4, CXCR1 | CXCR4 2/4885CYP3A4 1591/4885CYP2D6 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.